Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Compass Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
Eli Lilly and Company
BeOne Medicines
Accent Therapeutics
Seagen Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
SEED Therapeutics, Inc.
Dana-Farber Cancer Institute
Normunity AccelCo, Inc.
BioNTech SE
NiKang Therapeutics, Inc.
USWM, LLC (dba US WorldMeds)
IDEAYA Biosciences
MacroGenics
SystImmune Inc.
Pheon Therapeutics
MOMA Therapeutics
Doma Biopharmaceutical(Suzhou)Co., Ltd.
M.D. Anderson Cancer Center
Eli Lilly and Company
Seagen Inc.
GlaxoSmithKline
Sairopa B.V.
Fate Therapeutics
NextCure, Inc.
NeoTX Therapeutics Ltd.
Blueprint Medicines Corporation
Radiopharm Theranostics, Ltd
West China Hospital
SystImmune Inc.
Incyte Corporation
NiKang Therapeutics, Inc.
EtiraRx Australia Pty Ltd
Tempest Therapeutics
Pfizer
Exelixis
NextPoint Therapeutics, Inc.
Pfizer
Exelixis
Seagen Inc.
Seagen Inc.
Agenus Inc.
Compugen Ltd
Carisma Therapeutics Inc
Acepodia Biotech, Inc.